Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Past
Upcoming
Bookmark and Share

SABCS 2015

8 - 12 Dec 2015
TBC, San Antonio, United States of America
Videos
News
Biomarker driven clinical trials
Dr Oleg Gluz - West German Study Group Monchengladbach, Germany
Biomarker driven clinical trials ( Dr Oleg Gluz - West German Study Group Monchengladbach, Germany )
20 Dec 2016
Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELL...
Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, ...
Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )
17 Dec 2015
Survival outcomes from the CALGB 40603 study in triple-negative breast cancer
Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA
Survival outcomes from the CALGB 40603 study in triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )
17 Dec 2015
TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer p...
Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium
TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )
17 Dec 2015
Molecular evolution of breast cancer during neoadjuvant chemotherapy
Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway
Molecular evolution of breast cancer during neoadjuvant chemotherapy ( Prof Anne-Lise Børresen-Dale - Oslo University Hospital, Oslo, Norway )
17 Dec 2015
NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advan...
Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA
NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer ( Dr Samuel Jacobs - NSABP Foundation, Pittsburgh, USA )
17 Dec 2015
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in...
Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )
17 Dec 2015
Trastuzumab emtansine improves overall survival versus treatment of physician's ...
Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium
Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance ( Prof Hans Wildiers - University Hospital of Leuven, Leuven, Belgium )
17 Dec 2015
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response ...
Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy
Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX
TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy ( Dr Virginia Kaklamani - UT Health Science Center, San Antonio, TX )
17 Dec 2015
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study ( Dr Javier Cortes - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
17 Dec 2015
ER and FGFR1 interaction critical in endocrine resistant breast cancer
Dr Luigi Formisano - Vanderbilt University Nashville, USA
ER and FGFR1 interaction critical in endocrine resistant breast cancer ( Dr Luigi Formisano - Vanderbilt University Nashville, USA )
16 Dec 2015
Interrupting breast cancer treatment for young women who desire pregnancy
Dr Olivia Pagani and Dr Ann Partridge
Interrupting breast cancer treatment for young women who desire pregnancy ( Dr Olivia Pagani and Dr Ann Partridge )
16 Dec 2015
Treatment outcomes in patients with invasive breast cancer treated with neoadjuv...
Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA
Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging ( Prof Jennifer De Los Santos - University of Alabama, Birmingham, USA )
15 Dec 2015
Novel estrogen receptor-targeting agent represents ‘quantum leap’
Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA
Novel estrogen receptor-targeting agent represents ‘quantum leap’ ( Dr Ganesh Raj - UT Southwestern Medical Center, Dallas, USA )
15 Dec 2015
Ductal carcinoma in situ: Anastrozole versus tamoxifen
Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Ductal carcinoma in situ: Anastrozole versus tamoxifen ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
15 Dec 2015
Update on management of the axilla
Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA
Update on management of the axilla ( Dr Terry Mamounas - UF Health Cancer Center, Orlando, USA )
14 Dec 2015
Higher local recurrence after skin-sparing than simple mastectomy for DCIS
Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom
Higher local recurrence after skin-sparing than simple mastectomy for DCIS ( Prof Nigel Bundred, University of Manchester, Manchester, United Kingdom )
14 Dec 2015
Peri-operative lapatinib has profound antiproliferative effect in early breast c...
Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom
Peri-operative lapatinib has profound antiproliferative effect in early breast cancer ( Prof Nigel Bundred - University of Manchester, Manchester, United Kingdom )
14 Dec 2015
Guidelines and management of advanced breast cancer in limited resource settings
Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon
Guidelines and management of advanced breast cancer in limited resource settings ( Prof Nagi S. El Saghir - American University of Beirut, Beirut, Lebanon )
14 Dec 2015
New developments and technologies in hereditary cancer
Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...
New developments and technologies in hereditary cancer ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )
14 Dec 2015
Results of the CREATE-X trial
Dr Masakazu Toi - Kyoto University, Kyoto, Japan
Results of the CREATE-X trial ( Dr Masakazu Toi - Kyoto University, Kyoto, Japan )
14 Dec 2015
Hormonal treatments produce similar quality of life outcomes in DCIS
Prof Patricia Ganz - UCLA, Los Angeles, USA
Hormonal treatments produce similar quality of life outcomes in DCIS ( Prof Patricia Ganz - UCLA, Los Angeles, USA )
11 Dec 2015
No significant difference in recurrence rates among women with DCIS taking anast...
Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...
No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )
11 Dec 2015
Treating women with endocrine-resistant HR /HER2 advanced breast cancer
Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes...
Treating women with endocrine-resistant HR /HER2 advanced breast cancer ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )
11 Dec 2015
No significant difference in recurrence rates among women with DCIS taking anast...
Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United King...
No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )
11 Dec 2015
Patients with DCIS receiving anastrozole reported symptoms different from those ...
Prof Patricia Ganz - UCLA, Los Angeles, USA
Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life ( Prof Patricia Ganz - UCLA, Los Angeles, USA )
11 Dec 2015
Estrogen receptor mutations detected in plasma associated with worse overall sur...
Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA
Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer ( Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )
11 Dec 2015
Improved survival outcomes in women with HER2-negative breast cancer after neoad...
Dr Masakazu Toi - Kyoto university, Kyoto, Japan
Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy ( Dr Masakazu Toi - Kyoto university, Kyoto, Japan )
10 Dec 2015
Breast-conserving therapy yields better 10-year outcomes than mastectomy for ear...
Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...
Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015
Adding carboplatin to presurgery chemotherapy improved disease-free survival for...
Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany
Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )
10 Dec 2015
Mastectomy plus reconstruction has higher complication rates and costs than lump...
Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...
Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Dec 2015
Analysis of blood samples finds ESR1 gene mutations are prevalent and associated...
Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA
Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Dec 2015
Breast-conserving therapy yielded better outcomes than mastectomy for early-stag...
Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Net...
Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )
10 Dec 2015
Mastectomy plus reconstruction has higher complication rates and costs than lump...
Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Hous...
Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Dec 2015
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by AP...
Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA
Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B ( Dr Reuben Harris - Howard Hughes Medical Institute, Minneapolis, USA )
10 Dec 2015
Denosumab improves disease-free survival for postmenopausal patients with HR-pos...
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015
Test to identity which breast cancer patients will respond to platinum-based che...
Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...
Test to identity which breast cancer patients will respond to platinum-based chemotherapy ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )
9 Dec 2015
Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast...
Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA
Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers ( Dr Reuben Harris - Howard Hughes Medical Institute, Chevy Chase, USA )
9 Dec 2015
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant ...
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015
Denosumab improves disease-free survival for postmenopausal HR-positive breast c...
Prof Michael Gnant - Medical University of Vienna, Vienna, Austria
Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )
9 Dec 2015
Women with luminal A subtype of breast cancer did not benefit from adjuvant chem...
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
9 Dec 2015
Pathologic complete response to presurgery chemo improves survival for triple-ne...
Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA
Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )
9 Dec 2015

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation